{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T05:06:21Z","timestamp":1737781581152,"version":"3.33.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ajoc.2024.102216","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:54:34Z","timestamp":1730458474000},"page":"102216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment"],"prefix":"10.1016","volume":"36","author":[{"given":"Naveen R.","family":"Ambati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-0951","authenticated-orcid":false,"given":"Christopher D.","family":"Riemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajoc.2024.102216_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/24741264221135799","article-title":"Intraocular methotrexate for the treatment and prevention of proliferative vitreoretinopathy: a review","volume":"7","author":"McAllister","year":"2022","journal-title":"J Vitreoretinal Dis"},{"issue":"10","key":"10.1016\/j.ajoc.2024.102216_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3928\/23258160-20220920-04","article-title":"Intravitreal methotrexate for the prevention and treatment of proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a systematic review","volume":"53","author":"Balas","year":"2022","journal-title":"Ophthalmic Surgery Lasers Imaging Retina"},{"key":"10.1016\/j.ajoc.2024.102216_bib3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajoc.2024.102216_bib4","article-title":"Methotrexate for prevention of proliferative vitreoretinopathy in patients with\u2014proliferative vitreoretinopathy in the fellow eye","author":"Riemann","year":"2022","journal-title":"Paper presentation at the Annual Meeting Retina Soc"},{"year":"2015","series-title":"The Use of Intraoperative Methotrexate Infusion to Prevent Proliferative Vitreoretinopathy","author":"Riemann","key":"10.1016\/j.ajoc.2024.102216_bib5"},{"year":"2011","series-title":"Early Experience with Intraoperative Intravitreal Methotrexate Infusion during Vitrectomy - Is There a Role in the Prevention of Proliferative Vitreoretinopathy? Poster Presentation at the Retina Society Meeting in Rome","author":"Riemann","key":"10.1016\/j.ajoc.2024.102216_bib6"},{"author":"Franklin","key":"10.1016\/j.ajoc.2024.102216_bib8"},{"year":"2022","series-title":"Postoperative Intravitreal Methotrexate Injections Reduce Reoperations in Eyes with Proliferative Vitreoretinopathy and Diabetic Retinopathy. Paper Presentation at the Annual Meeting of the ASRS","author":"Franklin","key":"10.1016\/j.ajoc.2024.102216_bib9"},{"issue":"5","key":"10.1016\/j.ajoc.2024.102216_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/24741264221076357","article-title":"Systemic and intraocular methotrexate for the prevention and treatment of proliferative vitreoretinopathy in children with rhegmatogenous retinal detachment and underlying inflammatory disease","volume":"6","author":"Al-Moujahed","year":"2022","journal-title":"J Vitreoretin Dis"},{"issue":"3","key":"10.1016\/j.ajoc.2024.102216_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1159\/000526091","article-title":"Vitrectomy with silicone oil tamponade and single-dose intravitreal methotrexate for recurrent retinal detachment with proliferative vitreoretinopathy","volume":"13","author":"Babel","year":"2022","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2024.102216_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.51329\/mehdiophthal1452","article-title":"Intravitreal methotrexate infusion for prophylaxis of proliferative vitreoretinopathy after pars plana vitrectomy for rhegmatogenous retinal detachment","volume":"11","author":"Fouad","year":"2022","journal-title":"Med Hypothesis, Discov Innovation (MEHDI) Ophthalmol"},{"key":"10.1016\/j.ajoc.2024.102216_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000004046","article-title":"The role of intravitreal methotrexate as an adjunct to local or systemic corticosteroids in vitrectomy for rhegmatogenous retinal detachment and choroidal detachment: a pilot study","author":"Chahar","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.ajoc.2024.102216_bib14","article-title":"Proliferative vitreoretinopathy: an update on the current and emerging treatment options","author":"Ferro Desideri","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajoc.2024.102216_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ICB.0000000000001252","article-title":"Rescue intravitreal methotrexate treatment following early recognition of proliferative vitreoretinopathy","volume":"17","author":"Alabi","year":"2023","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"10.1016\/j.ajoc.2024.102216_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/jop.2022.0078","article-title":"Pharmacological therapy of proliferative vitreoretinopathy: systematic in vitro comparison of 36 pharmacological agents","volume":"39","author":"Tersi","year":"2023","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"3","key":"10.1016\/j.ajoc.2024.102216_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3928\/23258160-20230220-01","article-title":"Low-dose intravitreal methotrexate for proliferative vitreoretinopathy","volume":"54","author":"Ullah","year":"2023","journal-title":"Ophthalmic Surgery, Lasers Imaging Retina"},{"issue":"6","key":"10.1016\/j.ajoc.2024.102216_bib18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.survophthal.2021.02.011","article-title":"Congenital aniridia \u2013 a comprehensive review of clinical features and therapeutic approaches","volume":"66","author":"Landsend","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajoc.2024.102216_bib19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ajo.2005.07.035","article-title":"A progressive anterior fibrosis syndrome in patients with postsurgical congenital aniridia","volume":"140","author":"Tsai","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2024.102216_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/humu.1380060109","article-title":"Three novel aniridia mutations in the human PAX6 gene","volume":"6","author":"Martha","year":"1995","journal-title":"Hum Mutat"},{"year":"2014","series-title":"Personal Communication","author":"Michael","key":"10.1016\/j.ajoc.2024.102216_bib21"},{"key":"10.1016\/j.ajoc.2024.102216_bib22","article-title":"Aniridic fibrosis syndrome [image series]","author":"Riemann","year":"2013","journal-title":"ASRS Retina Image Bank"},{"key":"10.1016\/j.ajoc.2024.102216_bib23","series-title":"StatPearls","article-title":"Aniridic fibrosis syndrome","author":"Moshirfar","year":"2023"},{"issue":"10","key":"10.1016\/j.ajoc.2024.102216_bib24","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624002263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624002263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:39:36Z","timestamp":1737693576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993624002263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S2451993624002263"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102216","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102216"}}